论文部分内容阅读
最近,美国FDA抗病毒药物咨询委员会以不记名投票方式否决Viro Pharma公司的抗感冒新药普利康纳利(ple-conaril,Picovir),该品申请用于由微小RNA病毒(picornavi-ral)引起的急性上呼吸道感染(普通感冒)成年患者的治疗。委员会总体上认同了普利康纳利可缩减感冒症状期1~1.5天的中
Recently, the FDA Advisory Committee on Antiviral Drugs (VAC) denied Viro Pharma’s anti-influenza drug ple-conaril (Picovir) by secret ballot, which is intended for use by the picornavi-ral Acute upper respiratory tract infection (common cold) Treatment of adult patients. In general, the committee agreed that Pulcanalelli could reduce the duration of symptoms by 1 to 1.5 days